Loading clinical trials...
Loading clinical trials...
Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Conditions
Interventions
Dasatinib
Locations
22
Germany
Robert Bosch Krankenhaus
Stuttgart, Baden-Wurttemberg, Germany
Klinikum der Universität Regensburg
Regensburg, Bavaria, Germany
University Hospital of Frankfurt, Medical Dept. II
Frankfurt am Main, Hesse, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Universitätsklinik Münster
Münster, North Rhine-Westphalia, Germany
Start Date
November 1, 2011
Primary Completion Date
September 1, 2015
Completion Date
September 1, 2015
Last Updated
January 26, 2022
NCT01914484
NCT03821727
Lead Sponsor
Goethe University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions